Parabilis Medicines, Inc. PBLS
ASignal's systematic analysis rates PBLS as Neutral.
Reflects the latest available analysis · analyzed Nov 4, 2026
The case on PBLS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $1.12B in total cash
- Low debt-to-equity ratio of 0.05x indicating strong financial health
- High current and quick ratios suggesting robust liquidity
- MACD histogram turning positive, indicating potential momentum shift upward
- Negative operating margin at -34382.43%
- Extremely high price-to-sales ratio at 25341.01x
- Negative EV/EBITDA of -15.02x indicating unprofitable operations
- Forward P/E of -13.88x suggests no near-term profitability
- No Reddit mentions, indicating lack of retail investor interest
- Only one news source (Yahoo), limiting sentiment visibility
See the full verdict on PBLS
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PBLS
Most investors never get a second opinion, let alone several. ASignal runs PBLS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.